Central Sensitization: Why Personal Injury Pain Outlasts the Physical Injury

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | September 18, 2024 | 9 min read

One of the most common challenges in PI cases is explaining why patients still hurt months after tissue has healed. The answer is central sensitization — a documented neurological state in which the spinal cord's pain-processing circuitry remains amplified long after the original injury resolves. Understanding this mechanism explains why gabapentinoids, SNRIs, and CGRP drugs are medically necessary.

Central Sensitization: Why Personal Injury Pain Outlasts the Physical Injury

One of the most persistent challenges in personal injury litigation is explaining ongoing pain to a skeptic. Defense attorneys and adjusters assume that once tissue heals, pain should resolve. If the patient still hurts six months after an accident where they suffered a "soft tissue injury," the defense argues exaggeration.

The neuroscience says otherwise. Central sensitization — a well-documented, extensively studied neurological phenomenon — explains precisely how accident injuries create persistent pain that outlasts tissue healing. Understanding this mechanism allows PI attorneys to present ongoing pain as a scientifically legitimate injury, not a subjective complaint.

[!KEY] Central sensitization is the neurological mechanism that explains why PI patients still hurt months after tissue has healed — it is not imagined pain but pain generated by a nervous system that was structurally rewired by the original trauma, and the medications prescribed to treat it are the pharmacological documentation of that ongoing neurological injury.

What Is Central Sensitization?

Central sensitization is a state of amplified pain processing in the central nervous system — specifically in the dorsal horn of the spinal cord and in the brain — in which the pain-signaling system becomes persistently activated even after the original peripheral injury heals.

Under normal circumstances, pain signals follow a proportional pathway:

Peripheral injury → nociceptors (pain sensors) activated → signal travels to spinal cord → relayed to brain → conscious pain perception

In central sensitization, the system becomes dysregulated:

The spinal cord's relay neurons become hyperexcitable
They respond more strongly to the same peripheral input
They begin to respond to inputs that normally don't cause pain (touch, pressure, warmth)
The brain's pain-processing centers become sensitized, amplifying output

The result: pain that is physiologically real but disproportionate to peripheral tissue damage. This is not imagined pain — it is pain generated by an injured nervous system that has been rewired by the original trauma.

How Accidents Cause Central Sensitization

The process begins at the injury site. When an accident causes tissue damage:

Peripheral sensitization: Local inflammation activates and sensitizes nociceptors at the injury site. Pain signals increase in frequency and intensity.
Spinal cord input: These amplified signals arrive at the dorsal horn of the spinal cord repeatedly and in high volume during the acute injury phase.
Synaptic strengthening: The repeated high-volume input causes NMDA receptors (N-methyl-D-aspartate) in spinal cord neurons to "wind up" — they become progressively more responsive to each subsequent input. This is called "central wind-up."
Structural changes: With sustained activation, the pain-processing synapses in the dorsal horn undergo structural changes — more receptors are expressed, inhibitory circuits are downregulated, and the pain amplification becomes semi-permanent.
Persistent pain: Even after peripheral tissue heals and nociceptor firing normalizes, the central sensitization state persists. The spinal cord continues amplifying signals. Pain continues.

Who Is Vulnerable to Central Sensitization?

Research identifies several factors that increase vulnerability to developing central sensitization after injury:

Initial pain severity: More severe acute pain produces stronger wind-up and a higher probability of central sensitization
Duration of untreated pain: Delayed treatment allows sensitization to become more entrenched
Psychological factors: Anxiety, depression, and PTSD after trauma — very common in PI patients — amplify central sensitization through descending pain facilitation pathways
Sleep disruption: Sleep is critical for the nervous system's ability to downregulate pain sensitization; sleep disruption from injury allows sensitization to persist
Pre-existing chronic pain: Prior sensitization lowers the threshold for new sensitization

For personal injury patients — who often experience severe acute pain, delayed treatment due to insurance issues, psychological trauma from the accident, and sleep disruption — virtually all the central sensitization risk factors are present simultaneously.

Conditions That Include Central Sensitization

Central sensitization is not a diagnosis in isolation — it is the neurological mechanism underlying several documented clinical syndromes that commonly arise after personal injury:

Chronic post-traumatic pain: Persistent pain after auto accidents that continues beyond tissue healing. Documented in the literature as a specific post-accident syndrome with neurological underpinnings.

Fibromyalgia: The widespread musculoskeletal pain, fatigue, and sleep disruption of fibromyalgia are now understood as a manifestation of central sensitization. Trauma is a documented precipitating trigger for fibromyalgia in predisposed individuals.

Post-traumatic migraine: The trigeminal sensitization that underlies post-traumatic migraine involves the same central sensitization mechanisms — the trigeminal pain pathway becomes persistently amplified by the original trauma.

Chronic whiplash: Long-term cervical pain after whiplash injury correlates with central sensitization markers — patients have generalized pressure pain hypersensitivity throughout the body, not just in the neck, indicating central rather than peripheral pain origin.

Medications That Target Central Sensitization

This is where the pharmacological record becomes critical for PI attorneys: the medications prescribed for central sensitization directly document that the treating physician has identified and is treating this specific neurological state.

Gabapentinoids (Gabapentin, Pregabalin, Horizant)

Alpha-2-delta calcium channel modulators reduce the overactive release of excitatory neurotransmitters in sensitized dorsal horn neurons. By reducing the calcium-channel-mediated release of glutamate and substance P at hyperactive spinal synapses, gabapentinoids directly target the central sensitization mechanism — dampening the amplified spinal pain processing.

A prescription for gabapentin or pregabalin in a PI patient documents: physician assessment that central sensitization-driven neuropathic pain is present and requires targeted pharmacological management.

SNRIs (Duloxetine, Milnacipran/Savella)

The spinal cord has descending pain inhibitory pathways from the brain that normally suppress pain amplification. In central sensitization, these inhibitory pathways are weakened, allowing sensitization to persist. SNRIs enhance serotonin and norepinephrine activity, strengthening these descending inhibitory pathways and reducing central sensitization.

A duloxetine prescription for a PI patient documents: physician assessment that descending pain inhibition is impaired — consistent with established central sensitization — and that SNRI treatment is warranted.

[!KEY] When a treating physician prescribes duloxetine months after a PI accident, that prescription documents a specific neurological finding — impaired descending pain inhibition consistent with central sensitization — not depression or drug-seeking; attorneys should preserve the prescriber's clinical notes explaining this distinction.

CGRP Medications (Gepants, Monoclonal Antibodies)

Post-traumatic migraine involves trigeminal central sensitization as a core mechanism. CGRP antagonists reduce the sensitization of the trigeminal pain pathway by blocking the key molecular signal that maintains its sensitized state.

Why Central Sensitization Explains Persistent Symptoms

For PI attorneys, central sensitization provides the scientific explanation for the clinical reality that patients present: the accident caused an injury, the injury sensitized the central nervous system, and that sensitized state persists and causes ongoing pain even as soft tissue heals.

This is not a subjective patient claim — it is a documented neurological process with measurable biomarkers, reproducible findings on functional MRI, and an established pharmacological response to treatments that target the central sensitization mechanism.

When a treating physician prescribes gabapentin, duloxetine, or a CGRP medication for a patient months or years after an accident, they are treating central sensitization. The prescription documents an ongoing neurological injury consequence — one that explains why the patient still hurts, and why ongoing treatment is medically necessary.

[!KEY] A pharmacy record showing gabapentin, duloxetine, and a CGRP medication prescribed in sequence after a single accident is pharmacological documentation of a central sensitization progression — each medication addition represents a clinical assessment that the prior treatment was insufficient and the neurological injury was deepening, directly supporting both ongoing damages and future medical cost projections.

[!NOTE] PI patients face virtually all the central sensitization risk factors simultaneously — severe acute pain, delayed treatment due to insurance disputes, psychological trauma from the accident, and sleep disruption — which explains why post-traumatic central sensitization is more persistent and harder to reverse than sensitization from other causes.

LienScripts covers gabapentinoids, SNRIs, and all CGRP medications used for central sensitization-related pain after personal injury at $0 upfront cost. Contact LienScripts.

Related Resources

Frequently Asked Questions

Is central sensitization a recognized medical diagnosis?

Yes. Central sensitization is extensively documented in peer-reviewed neuroscience and pain medicine literature. It has defined mechanisms (spinal cord wind-up, NMDA receptor dysregulation, descending inhibition impairment) and measurable correlates (pressure pain threshold testing, quantitative sensory testing). It is the recognized underlying mechanism of fibromyalgia, chronic post-traumatic pain, and chronic whiplash.

How can an attorney explain central sensitization to a jury?

A useful analogy: central sensitization is like a smoke detector that has been recalibrated — it now goes off from steam, not just smoke. The accident recalibrated the patient's pain alarm system. The system itself is now the injury, and medications like gabapentin and duloxetine are recalibrating it back toward normal. A clinical pharmacist expert or neurologist can explain this mechanism at a level appropriate for a lay jury.

Which medications specifically treat central sensitization?

Gabapentinoids (gabapentin, pregabalin, Horizant) reduce hyperactive calcium channel activity in sensitized spinal cord neurons. SNRIs (duloxetine, milnacipran/Savella) strengthen descending pain inhibitory pathways that are weakened in central sensitization. CGRP medications address trigeminal central sensitization in post-traumatic migraine. All of these medication classes document physician-identified central sensitization in PI cases.